Contents

Current Pharmaceutical Design, Volume 11 - Number 2

Editorial [ Hot Topic: Antidepressant Drug Design (Executive Editor: Lee E. Schechter)]

, 11(2): 143 - 144

Lee E. Schechter


DOI: 10.2174/1381612053382269




Increasing Hippocampal Neurogenesis: A Novel Mechanism for Antidepressant Drugs

, 11(2): 145 - 155

Jessica E. Malberg and Lee E. Schechter


DOI: 10.2174/1381612053382223




Opportunities to Discover Genes Regulating Depression and Antidepressant Response from Rodent Behavioral Genetics

, 11(2): 157 - 169

James J. Crowley and Irwin Lucki


DOI: 10.2174/1381612053382278




Animal Models of Depressive Illness: The Importance of Chronic Drug Treatment

, 11(2): 171 - 203

P. J. Mitchell and P. H. Redfern


DOI: 10.2174/1381612053382250




The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development

, 11(2): 205 - 225

Robert H. Ring


DOI: 10.2174/1381612053382241




Clinical Perspectives on Antidepressant Drug Development: A Critical Discussion

, 11(2): 227 - 231

M. A. Demitrack


DOI: 10.2174/1381612053382296




Hypericin - The Facts About a Controversial Agent

, 11(2): 233 - 253

A. Kubin, F. Wierrani, U. Burner, G. Alth and W. Grunberger


DOI: 10.2174/1381612053382287




History Repeats Itself: Pharmacodynamic Trends in the Treatment of Anxiety Disorders

, 11(2): 255 - 263

T. L. Schwartz, N. Nihalani, M. Simionescu and G. Hopkins


DOI: 10.2174/1381612053382214




Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions

, 11(2): 265 - 272

Eric X. Chen and Lillian L. Siu


DOI: 10.2174/1381612053382205




Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus

, 11(2): 273 - 280

Ritu Saini, William D. Tutrone and Jeffrey M. Weinberg


DOI: 10.2174/1381612053382232




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science